We are live on
!
Find out more
SEC
Seven Eight Capital Portfolio holdings
AUM
$1.11B
1-Year Est. Return
29.48%
This Fund
S&P 500
This Quarter
Est. Return
+6.96%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$342M
AUM Growth
+$51.1M
(+18%)
Cap. Flow
+$47.6M
Cap. Flow
% of AUM
13.91%
Top 10 Holdings %
Top 10 Hldgs %
10.44%
Holding
675
New
141
Increased
130
Reduced
57
Closed
344
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$4.02M |
| 2 |
Nike
NKE
|
+$3.8M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$3.69M |
| 4 |
BNY
Bank of New York Mellon
BNY
|
+$3.63M |
| 5 |
Costco
COST
|
+$3.41M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PNC Financial Services
PNC
|
+$3.04M |
| 2 |
Visa
V
|
+$2.98M |
| 3 |
Procter & Gamble
PG
|
+$2.96M |
| 4 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$2.94M |
| 5 |
CPGX
COLUMBIA PIPELINE GROUP IN COM STK (DE)
CPGX
|
+$2.82M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.97% |
| 2 | Industrials | 12.49% |
| 3 | Consumer Discretionary | 11.9% |
| 4 | Healthcare | 11.63% |
| 5 | Consumer Staples | 10.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Popular Inc
BPOP
$11.1B
| $283K | 0.08% |
+7,400
| New | +$263K |
|
|
DBD
277
DELISTED
Diebold Nixdorf Incorporated
DBD
| $283K | 0.08% |
+11,400
| New | +$303K |
|
278
Transocean
RIG
$5.45B
| $279K | 0.08% |
+26,168
| New | +$277K |
|
|
DFS
279
DELISTED
Discover Financial Services
DFS
| $278K | 0.08% |
4,919
+2,600
| +112% | +$149K |
|
280
Avery Dennison
AVY
$12.8B
| $276K | 0.08% |
3,548
+2,800
| +374% | +$214K |
|
281
Burlington
BURL
$23.7B
| $275K | 0.08% |
3,400
+2,500
| +278% | +$193K |
|
282
Keurig Dr Pepper
KDP
$42.3B
| $274K | 0.08% |
3,000
+100
| +3% | +$9.47K |
|
|
GNC
283
DELISTED
GNC Holdings, Inc.
GNC
| $274K | 0.08% |
+13,401
| New | +$294K |
|
284
Trane Technologies
TT
$99.9B
| $271K | 0.08% |
3,984
-10,700
| -73% | -$713K |
|
285
Nabors Industries
NBR
$1.18B
| $270K | 0.08% |
444
-438
| -50% | -$216K |
|
286
Pacira BioSciences
PCRX
$1.03B
| $270K | 0.08% |
7,901
+6,000
| +316% | +$235K |
|
287
KB Home
KBH
$3.54B
| $268K | 0.08% |
+16,619
| New | +$262K |
|
288
Navient
NAVI
$833M
| $267K | 0.08% |
+18,475
| New | +$257K |
|
289
Acuity Brands
AYI
$10.2B
| $265K | 0.08% |
1,000
+800
| +400% | +$213K |
|
290
Akamai
AKAM
$16B
| $262K | 0.08% |
+4,952
| New | +$265K |
|
291
IDEX
IEX
$17.2B
| $262K | 0.08% |
2,800
-2,200
| -44% | -$199K |
|
292
Thor Industries
THO
$4.1B
| $254K | 0.07% |
3,000
-1,100
| -27% | -$85.5K |
|
293
Flex
FLEX
$37.7B
| $253K | 0.07% |
24,695
-23,754
| -49% | -$231K |
|
294
L3Harris
LHX
$55.7B
| $253K | 0.07% |
+2,759
| New | +$245K |
|
|
NFX
295
DELISTED
Newfield Exploration
NFX
| $247K | 0.07% |
+5,689
| New | +$250K |
|
296
Western Alliance Bancorporation
WAL
$8.95B
| $244K | 0.07% |
6,500
-7,000
| -52% | -$249K |
|
297
Coeur Mining
CDE
$15.2B
| $242K | 0.07% |
+20,460
| New | +$280K |
|
|
TWX
298
DELISTED
Time Warner Inc
TWX
| $242K | 0.07% |
+3,034
| New | +$237K |
|
299
Lennar Class A
LEN
$20.9B
| $241K | 0.07% |
5,996
-13,342
| -69% | -$591K |
|
|
SYNH
300
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $241K | 0.07% |
5,400
+3,700
| +218% | +$160K |
|
Similar funds
PP
ECM
GCAC
CAM
D
GFS
FTIS
AIA
Seven Eight Capital's Q3 2016 Portfolio in Review
As of Q3 2016, Seven Eight Capital held 675 positions worth $342M, up 18% from $291M the previous quarter. Its ten largest holdings account for 10% of the portfolio.
Seven Eight Capital deployed $47.6M of net new capital in Q3 2016, opening 141 new positions and adding to 130 existing holdings. Its largest new stake was Teva Pharmaceuticals: 77,100 shares worth $3.55M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, down from 17% a quarter earlier, followed by Industrials and Consumer Discretionary.
On the sell side, the largest reduction was Mastercard, an estimated $2.55M trimmed.
- Seven Eight Capital's largest Q3 2016 buy was Teva Pharmaceuticals: 77,100 shares worth $3.55M.
- Seven Eight Capital added most to Bristol-Myers Squibb in Q3 2016, an estimated $3.69M increase.
- Seven Eight Capital's biggest Q3 2016 reduction was Mastercard, cutting an estimated $2.55M.
- Seven Eight Capital fully exited PNC Financial Services in Q3 2016, selling an estimated $3.04M.
- Seven Eight Capital's ten largest holdings make up 10% of its $342M portfolio in Q3 2016.
- Seven Eight Capital opened 141 new positions and closed 344 in Q3 2016.
- Seven Eight Capital's portfolio value rose 18% quarter-over-quarter to $342M.
Based on Seven Eight Capital's 13F filing for Q3 2016, filed 14 Nov 2016.